BioFreedom -Model BA9 -Designed for Vascular Stent Technologies

SHARE

BA9, an effective Cytostatic Limus Drug: Rapid 28 day BA9 transfer to the vessel wall achieved through enhanced high lipophilicity delivering: Greater Local Bioavailability. Targeted Drug Release. Local tissue warehousing allowing Sustained Tissue Release, with Therapeutic Effect up to 100 days12,13. Longer Half Life than other commonly used Limus Drugs, approximately 20 days in tissue12,13. Potent Neointimal Suppression.

Most popular related searches

Increasing Safety and Effiacy
By leaving a bare metal stent luminal surface, BioFreedom promotes rapid reendothelialization and improves the healing process14 and allows for ultra-short 1 month DAPT.